In this article
🧪 Load this blend into the DIY blend calculator →
What it is
Tesamorelin with Ipamorelin is a two-part research combination. Tesamorelin is a stabilized GHRH analog, meaning it is a lab-made molecule that closely copies a natural signaling protein called growth hormone releasing hormone (GHRH). Research has focused on this molecule in connection with visceral fat, the fat stored deep in the belly around the organs. Ipamorelin is a selective GHRP (growth hormone releasing peptide), a small molecule that sends a separate but related signal along the same pathway.
Why these are combined
Tesamorelin is the GHRH analog most closely tied in the published literature to visceral adipose tissue research. "Visceral adipose tissue" just means the deep fat stored around the organs. Because of that focus, this blend is seen as the GH-axis pairing with the strongest metabolic lean. The GH axis is simply the body's chain of signals that controls growth hormone release. This combination sits at the metabolism-focused end of that chain.
The Ipamorelin component adds a complementary GHRP pulse. Think of Tesamorelin as one key turning a lock, and Ipamorelin as a second key that fits a nearby lock on the same door. Together they engage the pathway from two angles, which is the same approach seen in other GH-axis research blends.
Key point: This pairing is the GH-axis combination with the strongest metabolic focus, joining targeted visceral fat research with a complementary peptide pulse.
The components
- Tesamorelin, a stabilized GHRH analog studied for visceral fat research.
- Ipamorelin, a selective GHRP and secretagogue (a secretagogue is a molecule that prompts the release of another substance).
Reconstitution and blending
Both components are reconstituted (dissolved back into liquid form) using bacteriostatic water. Bacteriostatic water is purified water with a small preservative added to slow bacterial growth inside the vial. Tesamorelin is noted in the literature as more sensitive to rough handling, so gentle mixing and cold storage are standard practice at the bench.
Our reconstitution and DIY blend calculators handle the per-cartridge volumes and storage timing once you have decided what compounds share a cartridge.
Status in sport
Both Tesamorelin and Ipamorelin are banned in competitive sport under WADA S2. WADA is the World Anti-Doping Agency, and S2 is the category covering growth hormone releasing factors and secretagogues. This ban applies at all times, not just during competition.
Related reading
- Tesamorelin
- Ipamorelin
- Full peptide reference library and stacking guide
- Reconstitution and blend calculators
Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.
Frequently asked questions
What is the difference between Tesamorelin and Ipamorelin in GH-axis research?
Tesamorelin is a stabilized GHRH analog that mimics growth hormone releasing hormone; Ipamorelin is a selective GHRP secretagogue. They act on separate but related receptor pathways, engaging the GH axis from two complementary angles.
Why is Tesamorelin considered the most metabolic-focused GHRH analog in research?
Published literature has most closely studied Tesamorelin in connection with visceral adipose tissue, deep fat stored around the organs, giving it the strongest metabolic-lean association of any GHRH analog in the research record.
Are Tesamorelin and Ipamorelin banned in competitive sport?
Yes. Both are banned year-round under WADA S2, the category covering growth hormone releasing factors and secretagogues. The ban applies at all times, not only during competition.
What the research community gets wrong about Tesamorelin and Ipamorelin
- They are not two names for the same thing. Tesamorelin is a GHRH analog and Ipamorelin is a GHRP. In the literature they bind different receptors, so treating one vial as a stand-in for the other is a labeling mistake, not a shortcut.
- "Stabilized" does not mean rugged. Tesamorelin is built to resist breakdown better than natural GHRH, but published handling notes still describe peptides like it as sensitive to heat, shaking, and contact with air. Gentle swirling and cold storage are standard at the bench.
- The number on the vial is not all peptide. Lyophilized powder usually includes bulking agents and salts, so the net peptide mass is lower than the total powder weight. Assuming the whole vial is peptide throws off any volume math for a shared cartridge.
- "Selective" is a receptor description, not a quality grade. Ipamorelin was characterized as selective because, in the original study, it raised growth hormone signaling in the test system without some off-target effects seen with older secretagogues. That is a finding about receptor behavior, not a claim about anything you would measure in a person.
- Reconstituted does not mean shelf-stable. Once bacteriostatic water is added, the vial holds a working liquid with a limited window. The preservative slows bacterial growth, it does not stop the peptide from degrading over time in warm conditions.
From our bench: If you have reconstituted a Tesamorelin plus Ipamorelin cartridge, we would like your real notes. How long did each powder take to fully dissolve after adding bacteriostatic water, and did you see any cloudiness or leftover flecks with gentle swirling versus a harder mix? Tell us the storage temperature you held the cartridge at and how the solution looked after a few days. Share your actual observations, with no guessing, and we may add them to this page.
Sources
- Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
- Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
- Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
- Tesamorelin, PubChem Compound Summary (CID 16137828), NIH/NLM
- Raun et al., Ipamorelin, the first selective growth hormone secretagogue, Eur J Endocrinol 1998 (PMID 9849822)
- Falutz et al., Metabolic effects of a growth hormone-releasing factor (tesamorelin) in patients with HIV, N Engl J Med 2007 (PMID 18057338)
✔ Reviewed by Bryan Le, PharmD, RPh
Bryan is a licensed pharmacist (Doctor of Pharmacy, Registered Pharmacist). Reconstituting lyophilized preparations is core pharmacy practice, so he reviews The Lab’s content for technical accuracy and to keep it within a research-and-education scope, with no medical or dosing advice. View profile on LinkedIn.
